We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biotech Manufacturers to Develop Better Nucleic Acid Sample Preparation Protocols

By LabMedica International staff writers
Posted on 02 Nov 2014
Beckman Coulter Life Sciences\' Biomek 4000 automated liquid handling system
The Biomek 4000 automated liquid handling system (Photo courtesy of BECKMAN COULTER, INC - Danaher)
Manufacturers of biotech equipment and reagents are cooperating to ease and simplify protocols for preparing samples to be analyzed by advanced next generation sequencing platforms.

The success of techniques such as next-generation sequencing, microarrays, and library construction is contingent upon the precise and accurate processing of DNA and RNA. Library preparation of nucleic acids relies on a coordinated series of standard molecular biology reactions, and preparation of high quality libraries at high yield is a critical first step in the next generation sequencing workflow. The necessity for improved reagents and protocols for library preparation is growing in parallel with the increase in the number of applications for next generation sequencing.

To develop these new protocols, the instrument manufacturer Beckman Coulter Life Sciences (Nyon, Switzerland) will be collaborating with the reagent manufacturer New England Biolabs, Inc. (Ipswich, MA, USA). Beckman Coulter produces advanced automated liquid handling systems such as the Biomek 4000. New England Biolabs manufactures a line of highly pure "NEBNext" reagents that facilitate library preparation of DNA or RNA for downstream applications such as next generation sequencing and expression library construction.

It is planned that Beckman Coulter will use its extensive experience in automated next generation sequencing sample preparation to develop, distribute, and support automation for New England Biolabs' NEBNext sample preparation reagent kits. New England Biolabs will provide technical expertise on the reagents, chemistry, and protocols.

“Beckman Coulter’s focus on providing our next generation sequencing customers a top-notch portfolio of automated sample preparation solutions makes a partnership with New England Biolabs, a world leading provider of quality reagent systems for molecular biology research, a natural fit,” said Alisa Jackson, senior marketing manager, automated genomics solutions at Beckman Coulter. “Our joint collaborations with scientific researchers have already led to the development of high-quality methods demonstrated to improve efficiency, throughput and results for some of the most challenging sample inputs.”

Related Links:

Beckman Coulter Life Sciences
New England Biolabs, Inc.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more